Expression of cysLT1 and cysLT2 Receptor in Chronic Hyperplastic Eosinophilic Sinusitis by Ouyang, Yuhui et al.
Acta Histochem. Cytochem. 42 (6): 191–196, 2009
doi:10.1267/ahc.09031
© 2009 The Japan Society of Histochemistry and Cytochemistry
Advance Publication
AHC Acta Histochemica et Cytochemica 0044-5991 1347-5800 Japan Society of Histochemistry and Cytochemistry Tokyo, Japan AHC09031 10.1267/ahc.09031 Regular Article
Expression of cysLT1 and cysLT2 Receptor in Chronic Hyperplastic Eosinophilic 
Sinusitis
Yuhui Ouyang1,3, Atsushi Kamijo1, Shin-ichi Murata2, Atsushi Okamoto1, 
Shuichiro Endo1, Ryohei Katoh2 and Keisuke Masuyama1
1Department of Otorhinolaryngology, Head and Neck Surgery, Interdisciplinary Graduate School of Medicine and Engineering, 
Faculty of Medicine, University of Yamanashi, 2Department of Human Pathology, Interdisciplinary Graduate School of Medicine and 
Engineering, Faculty of Medicine, University of Yamanashi, Yamanashi 409–3898, Japan and 3Beijing Institute of 
Otorhinolaryngology, Beijing Tongren Hospital, Beijing 100–730, China
Correspondence to: Keisuke Masuyama, M.D., Ph.D., Department of
Otorhinolaryngology, Head and Neck Surgery, Interdisciplinary
Graduate School of Medicine and Engineering, Faculty of Medicine,
University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409–
3898, Japan. E-mail: mkeisuke@yamanashi.ac.jp
?? Received September 15, 2009; accepted October 14, 2009; published online December 22, 2009
© 2009 The Japan Society of Histochemistry and Cy- Elevated production of cysteinyl leukotrienes (cysLTs) from sinus tissues and abundant
sinus eosinophils are characteristic features of chronic hyperplastic eosinophilic sinusitis
(CHS). CysLTs exert their action through G-protein-coupled receptors named cysLTs recep-
tor type I (cysLT1R) and type II (cysLT2R). These expressions of cysLT receptors in the
sinus mucosa have yet to be clarified and the relationship between eosinophilia and the
expression of these receptors remains obscure. We compared the expressions of cysLT1R
and cysLT2R in the sinus mucosa in patients with CHS, non-eosinophilic chronic sinusitis
(NECS), and control sinus tissues; and analyzed the correlation between the expression of
CysLTRs and the presence of sinus eosinophils by immunohistochemistry and real-time
PCR. A significantly higher percentage of eosinophils expressing cysLT2R protein was ob-
served in patients with CHS compared with NECS and controls. In addition, cysLT2R mRNA
expression in CHS was significantly higher than in NECS and controls. Furthermore, a
positive correlation was observed between cysLT2R mRNA expression and the number of
infiltrated eosinophils. In contrast, the cysLT1R mRNA expression did not differ significantly
among these groups. The effect of cysLTs on sinus eosinophils may be mediated through
the cysLT2R in patients with CHS. These results may suggest the therapeutic benefit of
cysLT2R antagonists in CHS.
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I. Introduction
Cysteinyl leukotrienes (cysLTs) are lipid mediators
that not only stimulate potent contractile activity for bron-
chial smooth muscles but also exert proinflammatory actions
both in the upper and lower airways. Those cysLTs act on
target organs through specific receptors. Seven-membrane
domain G-protein-coupled receptors, termed cysLT1 recep-
tor (cysLT1R) and cysLT2 receptor (cysLT2R), have been
cloned and characterized by pharmacological studies so far
[8, 15, 20, 24]. While cysLT1R binds LTD4 with high
affinity and binds LTC4 and LTE4 with low affinity [15],
cysLT2R binds to both LTC4 and LTD4 with equal affinity
[11]. Both receptors have been described to be co-expressed
in various tissues, though the distributions of these two re-
ceptors are likely to be slightly different. These differences
in ligand-binding affinity and distribution of cysLT1R and
cysLT2R suggest that they have different functions in vivo.
An elevated production of cysLTs from sinus tissues
has been reported in chronic hyperplastic eosinophilic si-
nusitis (CHS) [23]. CHS is characterized by the accumula-
tion of eosinophils, often concomitant with nasal polypsis
(NP), and frequently associated with asthma. Higashi et al.Ouyang et al. 192
[9] have shown that urinary LTE4 (U-LTE4) concentrations
in subjects with aspirin-tolerant asthma (ATA) with CHS
were higher than those in the patients with ATA with normal
sinuses. Furthermore, a significant decrease in the U-LTE4
concentration was observed after endoscopic sinus surgery
in those patients. These data indicate that sinus tissues may
exhibit an overproduction of cysLTs and that might be
indicative of relevance to eosinophilia.
CHS with NP is sometimes resistant to medical treat-
ment and often recurs regardless of endoscopic sinus sur-
gery, especially when tissue eosinophilia is prominent [6,
18]. Asthma, especially aspirin-sensitive asthma (ASA), is
believed to be one of the risk factors responsible for nasal
polyp recurrence [1]; however, the exact pathophysiology of
recurrence is still unknown. In these cases, an elevated pro-
duction of cysLTs has been suggested and the overproduc-
tion of cysLTs may alter the functional properties of sinus
eosinophils, thus leading to persistent inflammatory changes
of the sinus tissues, which are difficult to manage medically.
CysLT1R antagonists have been widely used in clinical
practice and demonstrated to be effective in controlling air-
way symptoms of asthma and allergic rhinitis. Sousa et al.
[22] have shown that the percentage of inflammatory leuko-
cytes expressing cysLT1R was significantly elevated in the
nasal mucosa of patients with ASA compared to ATA. This
may explain the increased responsiveness of the target or-
gans in these patients. However, the precise distribution and
role of cysLT2R, as well as cysLT1R, has yet to be clarified
in the sinus tissues.
The aim of this study is to examine the expression of
cysLT1R and cysLT2R on sinus mucosa of a group of
patients with CHS, a group with NECS, and healthy con-
trols; and to investigate the relationship between cysLTR
expression and eosinophilia.
II. Materials and Methods
Tissue preparation and diagnosis
Maxillary sinuse mucosal tissue was collected from
22 patients during endoscopic sinus surgery (ESS) proce-
dures done in the Department of Otorhinolaryngology at
Yamanashi University Hospital. For the control group, 5
subjects without chronic rhinosinusitis, who also underwent
surgery due to facial trauma and nasal tumors, were re-
cruited. Written informed consent was obtained from all
patients to provide these tissue samples, and the study
was approved by the Ethics Committee of the University of
Yamanashi Hospital. Diagnosis of chronic rhinosinusitis
(CRS) was based on the presence of symptoms longer than
12 weeks, consistent findings using rhinoscopy, a positive
computed tomography, and physical examination. Asthma
was diagnosed based on the presence of reversible air-
way obstruction (≥12% increase in FEV1 in response to a
bronchodilator) [23]. Five patients were given a diagnosis
of asthma. One of the patients with asthma proved to have
a history of severe bronchoconstriction and nasal symp-
toms after ingestion of nonsteroidal anti-inflammatory drugs.
The number of eosinophils per high-powered field (400×)
was counted 4 times, each at a different loci each time in
22 samples from the patients. Patients with an average
number of eosinophils >20 per high-powered field were
diagnosed as CHS, and those <20 per high-powered field
were diagnosed as NECS. In the patients with chronic rhino-
sinusitis, 11 were CHS, and 11 were NECS. All patients
with asthma were included in CHS. Very little eosinophil
infiltration was observed in the control sinus tissue. Ages
of the patients ranged from 17 to 77 (mean 53.5) years.
None of the patients had taken oral or intranasal cortico-
steroids or LT antagonists for at least one month prior to
surgery. Sinus mucosal specimens were immediately frozen
in liquid nitrogen or frozen in O.C.T. compound and stored
at –80°C for RNA extraction; at the same time, samples
were fixed in 10% formalin for immunohistochemistry.
Immunohistochemistry
Immunohistochemistry was performed, as described
elsewhere [5]. Rabbit polyclonal anti-human cysLT1R
(Cayman Chemical, Ann Arbor, MI, USA) and cysLT2R
antibody (MBL, Nagoya, Japan) were used for immuno-
histochemical analysis. These antibodies showed no cross-
reactivity of staining. Conventional procedures were used
for immunohistochemistry by the application of EnVision+
(Dako Corp., Carpinteria, CA, USA). The reaction product
was detected with 3,3'-diaminobenzidine chromogen (DAB,
Dako, Carpinteria, CA). The formalin-fixed and paraffin-
embedded sinus specimens were incubated with anti-
cysLT1R (1:200) after pretreatment in a microwave oven
(10 min at 350 watt 90°C) in citrate buffer and with 0.25
μg/mL trypsin (for 10 min at 37°C). The sections were
photographed by digital color-CCD camera (Olympus
BX50, Tokyo, Japan). Then, the sections were stained with
hematoxylin-eosin (H&E), and were photographed again
at the same areas on the biopsies. For cysLT2R, the speci-
mens were initially stained with H&E, and subsequently
photographed. After destaining of the H&E, the sections
were incubated with cysLT2R polyclonal antibody (1:20)
after pretreatment using an autoclave (20 min at 120°C)
[12]. The immunohistostained samples were photographed
again at the same areas on the biopsies. The specificity
of the cysLT1R and cysLT2R antibody was investigated
with the staining used normal rabbit immunoglobulin
(Dako) of the same paraffin-embedded tissues. The num-
bers of eosinophils expressing cysLT1R and cysLT2R were
objectively counted by comparison of the image of the
H&E and immunostaining of cysLT1R and cysLT2R at
the same areas on the biopsies.
RNA extraction and real time-PCR analysis
Total RNA was extracted from the sinus biopsy speci-
mens by using an RNeasy Mini kit (QIAGEN), then treated
with TURBO DNase (Ambion) for 60 min at 37°C. The
treated total RNA was reverse-transcribed with a Super-
Script First Strand System (Invitrogen) according to the
manufacturer’s instructions. Real-time PCR was performedcysLTR2 and Eosinophilic Sinusitis 193
with the ABI Prism 7500 Sequence Detection System
(Applied Biosystems). PCR reactions contained 40 ng
cDNA of samples, 1X Taqman Universal PCR Master mix
(Applied Biosystems), 200 nM of primer pairs, and 250 nM
of TaqMan probe in a final volume of 25 μl. PCR proto-
col consisted of 1 cycle at 95°C for 10 min followed by
50 cycles at 95°C for 15 s and at 60°C for 1 min. Gene-
specific primers and probes were purchased from Applied
Biosystems. The primers and probes for the cysLT1R, (5'-
TGGATGAAACAGGAAATCTGACAGT, 5'-TACAAGG
TGGAATACACTTGATTGC,  and 5'FAM-CTGCCACAT
GCCATGACACTATTGAT-TAMRA-3'), cysLT2 (5'-TAT
TTCCTGACCGTGCTGAGTGT,  5'-TGACATCAGAAGCC
GAAAG,  5'FAM-TGCGTTTCCTGGCAATGGTTCACC-
TAMRA-3') were used, and β-actin primer/probe pair
(Applied Biosystems) was used as an internal control gene.
The threshold cycle (CT) was recorded for each sample to
reflect the mRNA expression levels. The relative cysLTR
gene expression was determined by the dCT value method as
described previously [14].
Statistical analysis
Statistical analysis was performed using the SPSS
version 11.0 software program for Windows (SPSS Inc.,
Tokyo, Japan). Correlations between cysLTRs expression
and the eosinophil counts were evaluated by Pearson’s
correlation coefficient test using the SPSS statistical analy-
sis software package. Between-group comparisons were
performed using the Mann-Whitney U test. Differences
were considered to be significant at P values equal to or
less than 0.05.
III. Results
Immunohistochemistry
Figure 1 and Figure 2 demonstrate the examples of
immunohistochemical staining for cysLT1R and cysLT2R
in CHS, NECS, and controls. The immunoreactivity for
cysLT1R in the sinus mucosa was significantly detected in
the vascular endothelial cells, plasma cells, neutrophils, and
lymphocytes (Fig. 1B, D and F). In contrast, cysLT2R im-
munoreactivity was mainly detected in inflammatory cells,
such as eosinophils, neutrophils, plasma cells, and lympho-
cytes (Fig. 2B, D and F), and was only slightly detected in
the submucosal glands. However, the epithelial cells ex-
Fig. 1. Immunohistochemical staining of CysLT1R in the human
sinus mucosa. H&E staining and CysLT1R immunohistochemical
staining in chronic hyperplastic eosinophilic sinusitis (CHS) (A, B),
noneosinophilic chronic sinusitis (NECS) (C, D) and control tissues
(E, F) respectively. A, C, and E were stained by H&E after
immunohistostaining with anti-CysLT1R antibody (B, D and F).
CysLT1R-positive cells, which are marked by arrowheads, are
plasma cells, neutrophils and vascular endothelial cells. Eosino-
phils expressed little CysLT1R immunoreactivity. Magnification
×400.
Fig. 2. Immunohistochemical staining for CysLT2R in the human
sinus mucosa. H&E staining and CysLT2R immunohistochemical
staining in patients with CHS (A, B), NECS (C, D) and control tis-
sues (E, F) respectively. B, D, F were immunohistostained with
cysLT2R after staining and destaining of H&E (A, C, and E).
Staining was observed mainly on eosinophils. Magnification ×400.Ouyang et al. 194
pressed little or no cysLT1R or cysLT2R immunoreactivity.
The specificities of cysLT1Rand cysLT2R antibodies using
paraffin-embedded tissues were confirmed by the absence of
staining with normal rabbit immunoglobulins (data not
shown).
The percentages of eosinophils expressing cysLT1R or
cysLT2R were compared within the subjects with CHS,
NECS, and controls (Fig. 3). CHS patients showed a sig-
nificantly elevated percentage of eosinophils expressing
cysLT2R compared with those with NECS (P=0.006) and
controls (P=0.01) (CHS: median, 56.3; range, 42.6–72;
NECS: median, 29.8; range, 0–57.0; controls: median, 11;
range, 0–33) (Fig. 3B). These eosinophils also showed a
significantly elevated cysLT1R expression compared to
controls (P=0.02), although no significant differences
were observed between the percentages of eosinophils ex-
pressing cysLT1R in patients with CHS and NECS (P=0.62)
(CHS: median, 5.67; range, 0–14.3; NECS: median, 5.75;
range, 0–16.0; controls: median, 0) (Fig. 3A). In addition,
there was no significant differences in the amount of eosino-
phils expressing both cysLT1R and cysLT2R between
asthmatics and non-asthmatics.
Real-time PCR analysis
The expression of mRNA for cysLT1R and cysLT2R
was analyzed by quantitative real-time PCR. The median
relative expression levels of cysLT2R mRNA were 8.30 in
CHS, 1.95 in NECS, and 1.90 in controls. A significantly
higher expression level of cysLT2R mRNA was observed in
subjects with CHS compared to those with NECS (P=0.006)
and controls (P=0.047). Between the NECS and control
groups, there was no significant difference in cysLT2R
mRNA expression levels (P=0.69) (Fig. 4B). However, the
median relative expression levels of cysLT1R mRNA were
not significantly different among these three groups (1.52 in
CHS, 1.80 in NECS, 1.17 in controls) (Fig. 4A).
Furthermore, a significant correlation was found
between the relative expression levels of cysLT2R mRNA
and the eosinophil counts in the sinus mucosa (R=0.651,
P=0.0002) (Fig. 5B). However, there was no correlation
Fig. 3. Percentages of eosinophils expressing CysLT1R (A) and
CysLT2R (B) in patients with CHS (n=10), NECS (n=7) and con-
trols (n=3). A significantly elevated percentages of eosinophils
expressed CysLT2R in the patients with CHS compared with
NECS and controls. There was no significant difference in the per-
centages of eosinophils which expressed CysLT1R in the patients
with CHS compared with NECS. Mann-Whitney U test. NS, not
significant.
Fig. 4. Relative expression of CysLT1R (A) and CysLT2R (B)
mRNA in CHS (n=11), NECS (n=11), and controls (n=5). Expres-
sion of CysLT2R showed a significant increase in CHS patients
compared to NECS and controls. Between NECS patients and the
controls, there was no significant difference. However, the expres-
sion of CysLT1R was not significantly different among the three
groups. Mann-Whitney U test; NS, not significant.cysLTR2 and Eosinophilic Sinusitis 195
between cysLT1R mRNA and the number of eosinophils in
the sinus mucosa (R=0.001, P=0.96) (Fig. 5A).
IV. Discussion
This immunohistochemical study demonstrated that el-
evated expression of cysLT2R on sinus mucosal eosinophils
is confined to patients with CHS. In addition the eosinophils
showed no evidence of upregulation of cysLT2R in patients
with NECS compared to controls. In contrast, no elevated
expression of CysLT1R in sinus eosinophils was found in
patients with CHS in comparison to those with NECS.
The real-time PCR study has confirmed that cysLT2R
expression is elevated in the sinus mucosa in patients with
CHS compared with NECS. Furthermore, a positive correla-
tion between the sinus mucosal cysLT2R mRNA and sinus
eosinophil counts was observed but not between cysLT1R
mRNA and the number of sinus eosinophils. These results
are consistent with a previous study showing that CysLT2R
transcript expression is higher in eosinophils than in baso-
phils and neutrophils [10]. In addition, peripheral blood
eosinophils have demonstrated relatively high expression of
cysLT2R mRNA compared to cysLT1R [16]. Another study
showed upregulation of cysLT2R protein on eosinophils in
nonatopic asthma patients during asthma exacerbation,
suggesting a modulatory role of cysLT2R on eosinophils
in upper and lower airway inflammatory diseases [7]. The
mechanisms of preferential elevation of cysLT2R expres-
sion on sinus eosinophils compared to cysLT1R in CHS
remain to be clarified.
Sinus tissues are considered to be one of the main tis-
sues that produce cysLTs. Steinke et al. [23] have demon-
strated that a higher concentration of cysLTs is observed in
sinus tissues obtained from patients with CHS than in
healthy sinus tissues and noneosinophilic sinus tissues. In
addition, Higashi et al. [9] have shown that urinary LTE4
(U-LTE4) concentrations, which are considered to be the
most reliable parameter for monitoring the endogenous syn-
thesis of cysLTs, in subjects with AIA with CHS were high-
er than those in the patients with ATA with normal sinuses.
Furthermore, a significant decrease in the U-LTE4 concen-
tration was observed after endoscopic sinus surgery in those
patients. These sinus sections revealed a diffuse and marked
infiltration of eosinophils, thus suggesting eosinophils might
be a major source of leukotrienes (LTs) in the sinus tissues.
These findings indicate that sinus tissues abundant in
eosinophils may play a role even in CHS without asthma.
Two receptors for the cysLTs, termed the type I and
type II cysLT receptors (cysLT1R and cysLT2R, respective-
ly), have been identified and characterized [8, 15, 20, 24].
The cysLTs exert their actions through these specific recep-
tors and are known for their powerful bronchoconstriction
activity and their role in exacerbation of asthma. For these
reasons, cysLTs receptors have been examined mainly in
asthma patients. Previous reports have suggested that
cysLT1R is upregulated in ASA compared to ATA [4, 22].
However, there was no upregulation of cysLT1R in CD45+
cells observed between nonaspirin-sensitive asthma and
controls [4]. Accordingly, cysLT1R upregulation might be
confined to ASA. In this report, the immunohistochemial
study has shown that both cysLT1R and cysLT2R were
upregulated compared to controls in CHS. Maxillary sinus
mucosa was obtained and compared between the groups,
thus demonstrating that few inflammatory cells were present
in control sinus mucosa. This may explain why differences
could be detected between CHS and controls.
CysLT1R antagonists have been recognized as highly
effective and are widely used for allergic diseases such as
asthma and allergic rhinitis [3, 17, 19]. In addition, the effi-
cacy of cysLT1R antagonists (montelukast) in the treatment
of nasal polyposis has recently been reported [13]. In that
study, montelukast therapy improved nasal symptom scores
in about 70% of patients. However, 30% of patients re-
mained the same or worsened and it was likely to be more ef-
fective in the patients with perennial allergies. These reports
imply that cysLT1R may be more related to the pathophysi-
ology of allergies in the nose rather than the sinus diseases.
Shirasaki  et al. [21] have clearly demonstrated cysLT1R
expression on vascular endothelial cells and inflammatory
cells such as eosinophils, mast cells, and macrophages in the
Fig. 5. The correlation between the number of eosinophils and the
expression of CysLT1R (A), and CysLT2R (B) in all of the
patients. The relative expression of CysLT2R correlated with the
number of eosinophils in the sinus mucosa, whereas the relative
expression of CysLT1R did not correlate with the number of
eosinophils.Ouyang et al. 196
nose. Although nasal tissues have not been examined, the
upregulation of cysLT2R in the sinus tissues in this study
would suggest a different role of cysLTs in the sinus dis-
eases and may partly explain why a cysLT1R antagonist is
less effective in some of the patients with nasal polyposis.
The mechanisms of low level expression of cysLT1R
on eosinophils compared with cysLT2R within sinus mu-
cosa in CHS remain obscure. Interferon-gamma (IFN-γ) has
been shown to upregulate cysLT2R expression on peripheral
blood eosinophils in nonatopic patients, but with no effects
on cysLT1R expression [7]. Furthermore, the cysLT2R ex-
pression on eosinophils has been shown to be upregulated
during an exacerbation of asthma in nonatopic subjects,
but not in atopic patients. In remission, the expressions of
eosinophil cysLT1R and cysLT2R have been shown to
be downregulated. Airway inflammation by viral infection
such as rhinovirus is one of the triggers of asthma exacerba-
tions, which may be accompanied by leukocytes trafficking
and production of cysLTs and IFN-γ. It is likely that sinus
eosinophils are modulated through viral infections and show
preferential expression of cysLT2R rather than cysLT1R.
Another recent study has demonstrated that cysLT2R may
play a role in airway remodeling in mice [2]. Further studies
will be needed to determine whether cysLT2R can play a
role in paranasal tissue remodeling.
In summary, these data demonstrate that the cysLT2R
expression on sinus eosinophils was higher in patients with
CHS rather than those with NECS and controls. Further-
more, the increased cysLT2R mRNA expression was sig-
nificantly correlated with the number of sinus eosinophils.
These results suggest a possible role for cysLT2R in sinus
diseases and may offer therapeutic benefits with the use of
cysLT2R antagonists in these CHS patients. Further studies
will be necessary to address these issues.
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